Cargando…
Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
Over 80% of triple negative breast cancers express mutant p53. Mutant p53 often gains oncogenic function suggesting that triple negative breast cancers may be driven by p53 protein type. To determine the chromatin targets of this gain-of-function mutant p53 we used inducible knockdown of endogenous...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319483/ https://www.ncbi.nlm.nih.gov/pubmed/28232952 http://dx.doi.org/10.1038/s41523-016-0001-7 |
_version_ | 1782509388237373440 |
---|---|
author | Qiu, Wei-Gang Polotskaia, Alla Xiao, Gu Di, Lia Zhao, Yuhan Hu, Wenwei Philip, John Hendrickson, Ronald C. Bargonetti, Jill |
author_facet | Qiu, Wei-Gang Polotskaia, Alla Xiao, Gu Di, Lia Zhao, Yuhan Hu, Wenwei Philip, John Hendrickson, Ronald C. Bargonetti, Jill |
author_sort | Qiu, Wei-Gang |
collection | PubMed |
description | Over 80% of triple negative breast cancers express mutant p53. Mutant p53 often gains oncogenic function suggesting that triple negative breast cancers may be driven by p53 protein type. To determine the chromatin targets of this gain-of-function mutant p53 we used inducible knockdown of endogenous gain-of-function mtp53 in MDA-MB-468 cells in conjunction with stable isotope labeling with amino acids in cell culture and subcellular fractionation. We sequenced over 70,000 total peptides for each corresponding reciprocal data set and were able to identify 3010 unique cytoplasmic fraction proteins and 3403 unique chromatin fraction proteins. The present proteomics experiment corroborated our previous experiment-based results that poly ADP-ribose polymerase has a positive association with mutant p53 on the chromatin. Here, for the first time we report that the heterohexomeric minichromosome maintenance complex that participates in DNA replication initiation ranked as a high mutant p53-chromatin associated pathway. Enrichment analysis identified the minichromosome maintenance members 2–7. To validate this mutant p53- poly ADP-ribose polymerase-minichromosome maintenance functional axis, we experimentally depleted R273H mutant p53 and found a large reduction of the amount of minichromosome maintenance complex proteins on the chromatin. Furthermore a mutant p53-minichromosome maintenance 2 direct interaction was detected. Overexpressed mutant p53, but not wild type p53, showed a protein-protein interaction with minichromosome maintenance 2 and minichromosome maintenance 4. To target the mutant p53- poly ADP-ribose polymerase-minichromosome maintenance axis we treated cells with the poly ADP-ribose polymerase inhibitor talazoparib and the alkylating agent temozolomide and detected synergistic activation of apoptosis only in the presence of mutant p53. Furthermore when minichromosome maintenance 2–7 activity was inhibited the synergistic activation of apoptosis was blocked. This mutant p53- poly ADP-ribose polymerase -minichromosome maintenance axis may be useful for theranostics. |
format | Online Article Text |
id | pubmed-5319483 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-53194832017-02-21 Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer Qiu, Wei-Gang Polotskaia, Alla Xiao, Gu Di, Lia Zhao, Yuhan Hu, Wenwei Philip, John Hendrickson, Ronald C. Bargonetti, Jill NPJ Breast Cancer Article Over 80% of triple negative breast cancers express mutant p53. Mutant p53 often gains oncogenic function suggesting that triple negative breast cancers may be driven by p53 protein type. To determine the chromatin targets of this gain-of-function mutant p53 we used inducible knockdown of endogenous gain-of-function mtp53 in MDA-MB-468 cells in conjunction with stable isotope labeling with amino acids in cell culture and subcellular fractionation. We sequenced over 70,000 total peptides for each corresponding reciprocal data set and were able to identify 3010 unique cytoplasmic fraction proteins and 3403 unique chromatin fraction proteins. The present proteomics experiment corroborated our previous experiment-based results that poly ADP-ribose polymerase has a positive association with mutant p53 on the chromatin. Here, for the first time we report that the heterohexomeric minichromosome maintenance complex that participates in DNA replication initiation ranked as a high mutant p53-chromatin associated pathway. Enrichment analysis identified the minichromosome maintenance members 2–7. To validate this mutant p53- poly ADP-ribose polymerase-minichromosome maintenance functional axis, we experimentally depleted R273H mutant p53 and found a large reduction of the amount of minichromosome maintenance complex proteins on the chromatin. Furthermore a mutant p53-minichromosome maintenance 2 direct interaction was detected. Overexpressed mutant p53, but not wild type p53, showed a protein-protein interaction with minichromosome maintenance 2 and minichromosome maintenance 4. To target the mutant p53- poly ADP-ribose polymerase-minichromosome maintenance axis we treated cells with the poly ADP-ribose polymerase inhibitor talazoparib and the alkylating agent temozolomide and detected synergistic activation of apoptosis only in the presence of mutant p53. Furthermore when minichromosome maintenance 2–7 activity was inhibited the synergistic activation of apoptosis was blocked. This mutant p53- poly ADP-ribose polymerase -minichromosome maintenance axis may be useful for theranostics. Nature Publishing Group UK 2017-01-19 /pmc/articles/PMC5319483/ /pubmed/28232952 http://dx.doi.org/10.1038/s41523-016-0001-7 Text en © The Author(s) 2017 This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Qiu, Wei-Gang Polotskaia, Alla Xiao, Gu Di, Lia Zhao, Yuhan Hu, Wenwei Philip, John Hendrickson, Ronald C. Bargonetti, Jill Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer |
title | Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer |
title_full | Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer |
title_fullStr | Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer |
title_full_unstemmed | Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer |
title_short | Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer |
title_sort | identification, validation, and targeting of the mutant p53-parp-mcm chromatin axis in triple negative breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319483/ https://www.ncbi.nlm.nih.gov/pubmed/28232952 http://dx.doi.org/10.1038/s41523-016-0001-7 |
work_keys_str_mv | AT qiuweigang identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer AT polotskaiaalla identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer AT xiaogu identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer AT dilia identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer AT zhaoyuhan identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer AT huwenwei identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer AT philipjohn identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer AT hendricksonronaldc identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer AT bargonettijill identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer |